Myra Vision’s Post

MSc in medical sciences grad Constantin Mouzaaber is advancing ophthalmology with groundbreaking research on peroxisome-deficient retinal cells. In his convocation spotlight, he shares what drew him to his work and his plans for the future. Read it here: https://bit.ly/3VgT97N #UAlberta24

Today (March 26, 2024), we are happy to announce an online publication of the 5th peer-reviewed technical paper on the tolerance to decentration of our bi-aspheric premium intraocular lenses (IOL), Asqelio™ EDOF and Asqelio™ Trifocal IOLs in the Graefe's Archive for Clinical and Experimental Ophthalmology. The paper is now available as open access via the link below.   This study demonstrates that the bi-aspheric diffractive trifocal IOL yields very good visual performance across distances, fostering high satisfaction levels and minimal difficulties in daily activities.   This study investigated the in vitro tolerance to decentration of bi-aspheric IOLs with refractive phase-ring extended depth-of-focus (EDOF) and diffractive trifocal designs.   Thus, the results have shown the optical design of the Asqelio™ Trifocal IOL is robust to small decentrations, with virtually no change in MTF response for 0.25 mm decentration. For greater decentration levels, the MTF response is slightly reduced with increasing decentration. The Asqelio™ EDOF IOL design is also robust to decentration, as the MTF response is only minimally affected when increasing the decentration up to 0.75 mm.   Many thanks to all team members, doctors, the university that had contributed and collaborated on this study. The result certainly has convinced and encouraged us to make happy patients one-by-one. DOI: https://lnkd.in/eziWw8ec #ASTProducts #ASTVisionCare #Asqelio #AsqelioTrifocal #AsqelioEDOF #EDOFIOL #TrifocalIOL #IOLs #IOL #CataractSurgery #RefractiveSurgery

🔍 Discover the latest innovation in glaucoma treatment with the new Calibreye System! This breakthrough technology offers precise, minimally invasive solutions, ensuring better outcomes and enhanced patient care. Dive into the details and see how Calibreye is revolutionizing ophthalmology 👁. Read on this editorial by Sheybani Arsham, MD here: https://bit.ly/45UhB2O

"In February, we have been invited to participate in this prestigious ophthalmology event, with a special focus on oculoplastics. During our presentation, we will discuss the fascinating and contemporary topic of regeneration through stem cells, an innovative advancement that promises to transform the field of ocular medicine." #oculoplastic

🌟🔬 Coming soon live, from American Academy of Ophthalmology 2024! Join Dr. Austin Pereira as he delves into groundbreaking insights from Dr. Quan Dong Nguyen’s presentation on the Neptune Phase 2 Clinical Trial. Discover how Brepocitinib, an innovative JAK/TK inhibitor, is setting new standards in the treatment of non-infectious uveitis. 📈💊 Stay tuned for more updates as we bring you the latest in ophthalmic breakthroughs directly from Chicago! #AAO2024 #ClinicalTrials #Ophthalmology #InnovationInMedicine #ClinicianLink

Great news! We recorded the interactive session, so you can still benefit from all the insights we gained. 🎉   📽️ Watch the replay: https://bit.ly/3S3h2y3

👁💢 Breaking News: OCTA Predicts Faster Visual Field Loss! 💢👁 A new study from JAMA Ophthalmology reveals the power of Optical Coherence Tomography Angiography (OCTA) in predicting visual field progression in glaucoma patients! 🌟 https://bit.ly/4ag742P ⚠️ Rapid initial optic nerve head capillary density loss, as measured by OCTA, is linked to faster visual field MD loss and increased risk of event progression. 🔬 This groundbreaking research underscores the potential of OCTA in assessing glaucoma risk and guiding early interventions. 🚀 Credit: JAMA Ophthalmology #OCTA #Glaucoma #VisualHealth #MedicalScience #visualloss #meded #eMednews

🌟 Discover the successful Special Issue "Diagnostics and Therapeutics in Ophthalmology" in Journal of Personalized Medicine MDPI! 🎓 Guest Editor: Dr. Yousif Subhi 💌 #13 papers in this Special Issue; 22K+ views and 10+ citations 🔗 Read more: https://lnkd.in/gtajZuDA 🙌 2nd Edition (open): https://lnkd.in/gCTxh3up #Ophthalmology

Thanks to Dr. Rosetta Pietro for this opportunity and to Dr Gianmaria Barone and Francesco Santoru for their precious collaboration in publishing this study conducted at the Department of Ophthalmology, Humanitas San Pio X, Milan. The study evaluates the outcomes of transepithelial iontophoresis cross-linking (I-CXL) in managing early keratoconus in patients under 25. 📊 Key Findings: - **Patient Profile:** High visual acuity (LogMAR ≤ 0.2) and early keratoconus treated with I-CXL. - **Outcome Stability:** After a 24-month follow-up, no significant changes in key metrics such as CDVA, keratometry, or corneal thickness were observed. - **Safety and Effectiveness:** None of the patients exhibited keratoconus progression during the follow-up period. - **Potential Benefits:** I-CXL emerges as a minimally invasive option for less advanced patients, offering an alternative to standard epithelium-off CXL.

Did you know that two-thirds of the people living with moderate-to-severe vision impairment live in East, South and Central Asia? This week Roche is bringing together over 200 ophthalmologists from across 10 markets in Asia for our APAC Ophtha Week where we will discuss how to tackle this disproportionate burden. Over the course of two days, we’ll hear from experts about current challenges facing patients, the latest innovations in treatment, and the value of meaningful partnerships to advance the field of ophthalmology. We are looking forward to the opportunity to collaborate to shape the future of vision in APAC, a future where everyone enjoys the gift of clear vision. #AROW2024 #RocheOphthalmology #RocheOphthaAPAC Ref: Chen, D., Hee, J. Y., Ho, B., Mohan, P., & Greene, W. (2019). Ophthalmology in Asia. - M-TW-00005708